Narrative Review: Buprenorphine for Opioid-dependent Patients in Office Practice

Overview

Journal Ann Intern Med

Specialty General Medicine

Date 2008 May 7

PMID 18458279

Citations 24

Authors

Lynn E Sullivan

David A Fiellin

Affiliations

Soon will be listed here.

Abstract

The profile of opioid dependence in the United States is changing. Abuse of prescription opioids is more common than that of illicit opioids: Recent data indicate that approximately 1.6 million persons abuse or are dependent on prescription opioids, whereas 323,000 abuse or are dependent on heroin. Despite this prevalence, nearly 80% of opioid-dependent persons remain untreated. One option for expanding treatment is the use of buprenorphine and the buprenorphine-naloxone combination. Buprenorphine is a partial opioid agonist that can be prescribed by trained physicians and dispensed at pharmacies. This article addresses the clinical presentation of a patient with opioid dependence and describes the relatively new practice of office-based treatment with buprenorphine-naloxone. The different components of treatment; the role of the physician who provides this treatment; and the logistics of treating this growing, multifaceted patient population are also examined.

Citing Articles

Adaptive decision support for addiction treatment to implement initiation of buprenorphine for opioid use disorder in the emergency department: protocol for the ADAPT Multiphase Optimization Strategy trial.

Iscoe M, Diniz Hooper C, Levy D, Buchanan L, Dziura J, Meeker D BMJ Open. 2025; 15(2):e098072.

PMID: 39979056 PMC: 11842997. DOI: 10.1136/bmjopen-2024-098072.

A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood.

Romano I, Core S, Lee N, Mowry C, Van Rompay K, Huang Y Vaccine. 2023; 42(3):471-480.

PMID: 38160131 PMC: 10872394. DOI: 10.1016/j.vaccine.2023.12.077.

Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.

Qian G, Rao I, Humphreys K, Owens D, Brandeau M Drug Alcohol Depend. 2023; 243:109762.

PMID: 36621198 PMC: 9852082. DOI: 10.1016/j.drugalcdep.2022.109762.

User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.

Melnick E, Nath B, Dziura J, Casey M, Jeffery M, Paek H BMJ. 2022; 377:e069271.

PMID: 35760423 PMC: 9231533. DOI: 10.1136/bmj-2021-069271.

Descriptive Analysis of Inpatient and Outpatient Cohorts Seeking Treatment After Prescription Opioid Misuse and Medical Toxicology Evaluation.

Varney S, Wiegand T, Wax P, Brent J J Med Toxicol. 2021; 17(4):378-385.

PMID: 34402039 PMC: 8455734. DOI: 10.1007/s13181-021-00850-7.

References

. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997; 58(1):7-29. View

Fiellin D, Moore B, Sullivan L, Becker W, Pantalon M, Chawarski M . Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008; 17(2):116-20. DOI: 10.1080/10550490701860971. View

Barry D, Moore B, Pantalon M, Chawarski M, Sullivan L, OConnor P . Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med. 2007; 22(2):242-5. PMC: 1824745. DOI: 10.1007/s11606-006-0050-y. View

Amass L, Bickel W, Higgins S, Hughes J . A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994; 13(3):33-45. DOI: 10.1300/j069v13n03_04. View

Book S, Myrick H, Malcolm R, Strain E . Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient. Am J Psychiatry. 2007; 164(6):979. DOI: 10.1176/ajp.2007.164.6.979. View

Jones H . Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect. 2008; 2(2):4-20. PMC: 2851017. DOI: 10.1151/spp04224. View

OConnor P, Kosten T . Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998; 279(3):229-34. DOI: 10.1001/jama.279.3.229. View

McCance-Katz E, Moody D, Morse G, Friedland G, Pade P, Baker J . Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006; 43 Suppl 4:S224-34. DOI: 10.1086/508187. View

Greenwald M, Schuh K, Stine S . Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict. 2003; 12(4):365-74. View

10.

Becker W, Sullivan L, Tetrault J, Desai R, Fiellin D . Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2007; 94(1-3):38-47. DOI: 10.1016/j.drugalcdep.2007.09.018. View

11.

Sullivan L, Bruce R, Haltiwanger D, Lucas G, Eldred L, Finkelstein R . Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006; 43 Suppl 4:S191-6. DOI: 10.1086/508183. View

12.

Alford D, Compton P, Samet J . Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006; 144(2):127-34. PMC: 1892816. DOI: 10.7326/0003-4819-144-2-200601170-00010. View

13.

Stein M, Cioe P, Friedmann P . Buprenorphine retention in primary care. J Gen Intern Med. 2005; 20(11):1038-41. PMC: 1490248. DOI: 10.1111/j.1525-1497.2005.0228.x. View

14.

Strain E, Preston K, Liebson I, Bigelow G . Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther. 1995; 272(2):628-38. View

15.

Ives T, Chelminski P, Hammett-Stabler C, Malone R, Perhac J, Potisek N . Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006; 6:46. PMC: 1513222. DOI: 10.1186/1472-6963-6-46. View

16.

Amass L, Ling W, Freese T, Reiber C, Annon J, Cohen A . Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004; 13 Suppl 1:S42-66. PMC: 1255908. DOI: 10.1080/10550490490440807. View

17.

. Project MATCH (Matching Alcoholism Treatment to Client Heterogeneity): rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res. 1993; 17(6):1130-45. DOI: 10.1111/j.1530-0277.1993.tb05219.x. View

18.

Dasgupta A . The effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine. Am J Clin Pathol. 2007; 128(3):491-503. DOI: 10.1309/FQY06F8XKTQPM149. View

19.

Reid M, Weber M, Kerns R, Rogers E, OConnor P . Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002; 17(3):173-9. PMC: 1495018. DOI: 10.1046/j.1525-1497.2002.10435.x. View

20.

Ling W, Charuvastra C, Collins J, Batki S, Brown Jr L, Kintaudi P . Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998; 93(4):475-86. DOI: 10.1046/j.1360-0443.1998.9344753.x. View